Belgium Dermatology Drugs Market Analysis Report [2022-30]

Belgium Dermatology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Belgium Dermatology drugs market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as ThromboGenics, Galapagos, and UCB. The market is driven by teledermatology consultations, modest clinical trials, and awareness about dermatological health. The dermatology drug market in Belgium is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel.

ID: IN10BEPH008 CATEGORY: Pharmaceuticals GEOGRAPHY: Belgium AUTHOR: Dr. Vishwa Modhia

Buy Now

Belgium Dermatology Drugs Market Analysis Summary

By 2030, it is anticipated that the Belgium Dermatology drugs market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

The Royal Belgian Society for Dermatology and Venereology (RBSDV) is a group of dermatologists dedicated to advancing the understanding of skin conditions and disorders. In Belgium, 3.3% of men and 4.5% of women experienced severe or chronic skin disease in 2019. In Belgium, a variety of skin conditions are treated with a wide variety of dermatology medications.

Topical corticosteroids, topical retinoids, antihistamines, calcineurin inhibitors, antibiotics, analogues of vitamin D, and psoralen plus ultraviolet A (PUVA) therapy are a few of the most widely prescribed medications. As a result, the first wave of Covid-19 included the use of medical software, telemedicine, e-health, and m-health for dermatology consultations, all of which have significant market potential.

Market Dynamics

Market Growth Drivers

Increasing demand for cosmetic procedures with little to no downtime, like laser treatments and dermatological injectables. The development of telemedicine in dermatology has enabled patients to get consultations and treatments remotely. The growing demand for skin cancer screening and treatment services is a result of increased awareness of skin cancer and the value of early detection and treatment.

Market Restraints

Large-scale clinical trials have been challenging to carry out because of the small size of the Belgian population. This can discourage new competitors from entering the Belgian dermatology drug market.

Competitive Landscape

Key Players

UCB S.A. (BEL)
Galapagos NV (BEL)
ThromboGenics NV (BEL)
ViroMetrics NV (BEL)
Transgene S.A. (BEL)
Pfizer
Novo Nord
GlaxoSmithKline
Sanofi
Johnson & Johnson

Healthcare Regulations and Reimbursement Policies

In Belgium, the regulatory body responsible for overseeing the approval and marketing of dermatology drugs is the Federal Agency for Medicines and Health Products (FAMHP). Prior to being permitted to be marketed and sold in Belgium, all medications and medical devices must pass the FAMHP's evaluation of their quality, safety, and efficacy. The FAMHP can take action if any adverse events are reported and additionally monitors the post-marketing safety of approved products. This regulatory body is essential in ensuring that patients in Belgium have access to dermatology treatments that are both safe and efficient.

The National Institute for Health and Disability Insurance (RIZIV/INAMI) is responsible for managing dermatology medication reimbursement in Belgium. The RIZIV/INAMI decides which medications qualify for reimbursement based on the medication's safety and effectiveness, cost-effectiveness in comparison to alternative therapies, and necessity within the Belgian healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Dermatology Drugs Market Segmentation

The Dermatology Drugs Market is segmented as mentioned below

By Disease (Revenue, USD Billion):

Psoriasis
Acne Vulgaris
Atopic Dermatitis
Eczema
Rosacea
Itchthyosis
Vitiligo
Others

By Route Of Administration (Revenue, USD Billion):

Oral
Parenteral
Topical

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.